Uncategorized

[UMass Chan Medical School] Dr. Marcus Ruscetti, is one of 13 investigators to receive the prestigious 2026 Pershing Square Sohn Cancer Prize from the Pershing Square Sohn Cancer Research Alliance. Dr. Ruscetti will study how cells in the liver experiencing senescence create an immune-suppressive environment that enables pancreatic cancer metastasis.

[OICR] Four new research studies funded by the Ontario Institute for Cancer Research (OICR) will deliver innovations by maximizing the impact of existing research and making the most out of patient contributions. OICR is supporting the studies through CATALYST, a new funding stream for research that leverages available patient data and donated samples to advance new insights about detecting, diagnosing and treating cancer.

[British Journal of Cancer] Scientists conducted an integrated analysis of RNA sequencing data using established chemoresistant colorectal cancer (CRC) cell lines and publicly available single-cell transcriptomic datasets of clinical CRC samples to clarify the underlying mechanisms associated with acquired chemoresistance.

[Nature Cell Biology] Investigators showed a microwell cell-chip culture platform that enabled rapid, high-throughput generation of uniform micro-tumourspheres from limited breast cancer specimens, such as puncture biopsies, facilitating functional CSC enrichment and personalized drug testing within eight days.

[Clinical and Translational Oncology] The authors summarize the principal mechanisms of chemoresistance in gastric cancer and synthesize evidence on how microRNAs—derived from tumor cells and the tumor microenvironment—promote or reverse resistance to commonly used chemotherapeutic agents and targeted therapy/immunotherapies.

[Cleveland Clinic] The Women’s Alzheimer’s Movement (WAM) at Cleveland Clinic awarded grants for three of the most promising research projects in the field of gut-brain interactions, menopause, and sarcopenia.

[Nature Communications] Researchers identified astrocyte-derived kynurenic acid (KYNA), a neuroactive metabolite known to modulate multiple neurotransmitter receptor systems, including the N-methyl-D-aspartate receptor (NMDA), as a mediator of cognitive dysfunction in the context of aberrant astrocyte activity.

[Nature Communications] Investigators reported a synthetic peptidomimetic foldamer, M4, as a potent modulator of amyloid-β (Aβ) 42 aggregation. Biophysical analyses demonstrate that M4 binds Aβ with high affinity, inhibits oligomer formation, and remodels pre-existing aggregates.

[Advanced Healthcare Materials] Scientists presented a bioengineered assembloid system that integrates glioblastoma cells encapsulated in self-degradable 5% oxidized alginate microgel with dorsal forebrain organoids to recapitulate early tumor-host interactions during glioblastoma invasion toward the brain.

[BJC reports] Researchers addressed the therapeutic relevance of glioblastoma (GBM)’s molecular characterization, focusing on whether a proneural-vs-mesenchymal classification may describe GBM heterogeneity, correlate to stemness and CD44, and have a prognostic value in terms of temozolomide resistance.

[Communications Biology] Investigators developed an integrative discovery strategy to identify natural compounds that mitigate endoplasmic reticulum (ER)-stress-associated phenotypes across cellular and organismal models.

[Communications Biology] Scientists reported the generation of hiPSC-derived cerebellar organoids that are characterized by induction of rhombomere 1 cellular identity and followed by derivation of typical neuronal and glial cell types of the cerebellum.